The traditional approach to the diagnosis of primary adenohypophyseal cell proliferations uses hormone immunohistochemistry to classify pituitary neuroendocrine tumors (PitNETs). The routine application of immunolocalization of pituitary transcription factors (SF1, PIT1, TPIT, ERα, and recently GATA3) along with adenohypophyseal hormones has taught us critical lessons that are discussed in this communication. We point out that appropriate patient care requires accurate diagnosis and is critical in the era of precision medicine. A misdiagnosis can result in far greater health care costs than the cost of accurate tumor classification and may have other unintended consequences. We provide additional insights about confusing findings in genomic studies, emphasizing that high-quality pathology is essential for strong science and translational research.

诊断原发性腺垂体细胞增殖的传统方法使用激素免疫组织化学对垂体神经内分泌肿瘤 (PitNET) 进行分类。垂体转录因子（SF1、PIT1、TPIT、ERα 和最近的 GATA3）以及腺垂体激素的免疫定位的常规应用教会了我们在本次交流中讨论的重要课程。我们指出，适当的患者护理需要准确的诊断，这在精准医疗时代至关重要。误诊可能导致比准确肿瘤分类的成本高得多的医疗保健成本，并可能产生其他意想不到的后果。我们提供有关基因组研究中令人困惑的发现的更多见解，强调高质量的病理学对于强大的科学和转化研究至关重要。